1. Home
  2. NRT vs LUNG Comparison

NRT vs LUNG Comparison

Compare NRT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NRT

North European Oil Royality Trust

HOLD

Current Price

$8.83

Market Cap

81.0M

Sector

Energy

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.00

Market Cap

97.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRT
LUNG
Founded
1975
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Industrial Specialties
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.0M
97.1M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
NRT
LUNG
Price
$8.83
$2.00
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
34.7K
314.4K
Earning Date
05-29-2026
04-29-2026
Dividend Yield
10.18%
N/A
EPS Growth
N/A
7.64
EPS
0.70
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
$12.53
N/A
Revenue Growth
N/A
8.01
52 Week Low
$5.23
$1.13
52 Week High
$10.49
$2.89

Technical Indicators

Market Signals
Indicator
NRT
LUNG
Relative Strength Index (RSI) 49.41 50.36
Support Level $8.48 $1.20
Resistance Level $9.52 $2.16
Average True Range (ATR) 0.22 0.11
MACD -0.06 -0.02
Stochastic Oscillator 24.05 47.57

Price Performance

Historical Comparison
NRT
LUNG

About NRT North European Oil Royality Trust

North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: